

- ❖ Name & Designation : Mr. Manoj Kumar, DNB 3rd Year Resident.
❖ Address : Surgical Gastroenterology and Liver Transplant, Sir Ganga Ram Hospital, New Delhi-110060.
❖ Name of the International Conference/ Seminar/Symposium/ Workshop : Joint International Congress of ILTS, ELITA & Lacage 2014.
❖ Title of the abstract accepted : 1. Circulating regulatory T cells as markers of immune response to tolerance in living donor liver transplant receipts. 2. Predictors of intraoperative blood loss in living donors liver transplant receipts and its correlation with postoperative outcome.
❖ Date & Venue : 4-7 July, London, U.K.
❖ Money sanctioned : Rs 89,276/-
❖ Money reimbursed : Rs 89,276/-

Participation Report

Academic Highlights

ILTS - ELITA - LICAGE Joint Congress

1850 delegates from 57 countries!

The scientific sessions were outstanding as was the social program.

Speakers and participants from all three societies

4/6/14

On Liver Transplant excellence:

- Current challenges
- HCV- new Drugs
- HCC organ allocation
- Donor transmitted infections
- Outcomes after liver transplantation
- Optimising resources
- Alcoholic hepatitis
- Organ resuscitation

5/6/14

- Medical Care or Transplantation for Acute Liver Failure?
- Featured Symposium # 1: Risk Evaluation and Outcomes
- Is the Measurement of Physiological Reserve the Best Predictor of Outcomes?
- Composite Risk: Predicting Short and Long Term Outcomes

- Impact of Early Post-operative Morbidity on Long-term Patient Outcomes
- Featured Symposium # 2: HCC
- Impact of Rationing on Allocation for HCC
- Time for New Criteria in an Era of Effective Loco-regional Therapy
- Featured Symposium # 3: Pediatric
- Surgeons: What You Need to Know About Adult Recipient with Pediatric Liver Disease
- Liver Transplantation in a Newborn
- Pediatric Liver Allocation around the World – North America
- Pediatric Liver Allocation around the World – South America
- Pediatric Liver Allocation around the World – Europe
- Concurrent Oral Abstract Sessions:
 - Immunosuppression
 - Living Donor
 - Cardiac Evaluation and Outcomes
 - Outcomes I
- Concurrent Oral Abstract Sessions:
 - Viral Hepatitis
 - Surgical Techniques / Complications
 - Pediatrics
 - Patient Selection/Organ Allocation

Friday, June 6, 2014

- Plenary Abstract Session #1
- State-of-the-Art Lecture # 2
- Humoral Allimmunity and the Liver: Emerging Insights and Their Therapeutic Implications
- Featured Symposium # 4: Living Donor
- Are There Any Contraindications to Living Donor Liver Transplant?
- Is Living Donation a Barrier to Creating Effective Deceased Donor Transplantation?
- Featured Symposium # 5: Super Bugs, Emerging Drugs and Regulations
- Challenges in Management of Fungal Infections in Liver Transplant Recipients
- Donor Derived Infections and Regulatory Challenges
- Featured Symposium # 6: Liver Directed Cellular Therapy – Hope or Hype
- Current State of Human Hepatocyte Transplantation
- Use of Mesenchymal Stem Cells in Liver Disease
- T-Regulatory Cells for Tolerance in Liver Transplant Recipients

- IPS and ES Derived Hepatocytes

- Concurrent Oral Abstract Session:

- Anesthesia/Critical Care Medicine

- Tissue Injury/Immunology

- Malignancies

- Recurrent Disease

- Concurrent Oral Abstract Session:

- Outcomes II/Extended Criteria Donors

- Acute Liver Failure

- Surgical Video Session

- Late Breaking

Saturday, June 7, 2014

- Featured Symposium # 7: Surgical Techniques

- Technical Challenges: Deceased Donor Full Left and Full Right

- Latest Surgical Innovations in Living Donor Liver Transplantation

- New Developments in Organ Preservation: Normothermic Perfusion

- Multivisceral Transplantation for Complete Portomesenteric

Thrombosis

- Featured Symposium # 8: Extremes of the Immunologic Spectrum

Salvage Immunosuppression

- Etiology: Who Needs More?

- Etiology: Who Needs Less?
- Featured Symposium # 9: Living the Life: Making the Most of Your Liver Transplant
- Employment and Education
- Economic Burden for the Liver Transplant Recipient
- Featured Symposium # 10: Perioperative Management Controversies
- Management of Patients Receiving Marginal Grafts
- Management of the Living Donor Recipient
- Cardiac Output Monitoring and the Micro-circulation
- Featured Symposium # 11: Directed Antiviral Therapy for Hepatitis C
- Drug Interaction for HCV Post Liver Transplant - Debate
- Featured Symposium # 12: Acute Liver Failure
- Understanding the Coagulopathy of Acute Liver Failure
- Intracranial Pressure Monitoring and Management
- Immunoparesis: Infection and Outcome in Acute Liver Failure
- Featured Symposium # 13: Long-term Outcomes
- 20 Year Follow-up: An Adult Perspective

- 20 Year Follow-up: A Pediatric Perspective
- Are There Challenges in Getting Them to 20 Years?
- Long Term Outcomes of Multi-Organ Transplantation

New Development

ILTS Practice Guidelines

ILTS

Three New ILTS Guidelines: Living Donor Liver Transplantation, Liver Transplantation for Alcoholic Liver Disease and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension.

Screening for hepatocellular carcinoma in chronic liver disease

Guidelines recommend routine screening for hepatocellular carcinoma (HCC) in high-risk patients, but the strength of evidence supporting these recommendations is unclear. The purpose of this study is to review the benefits and harms of HCC screening in patients with chronic liver disease. The study selection included English-language trials and observational studies comparing screening versus no screening, studies of harms and trials comparing different screening intervals.

New drug that may cure hepatitis C is costly

A new drug with the power to cure a damaging liver disease is gaining users in Central Massachusetts — and raising concerns over its hefty price. Local insurer Fallon Health is asking physicians to seek prior approval before prescribing Sovaldi to patients with the viral disease hepatitis C, and doctors in the Reliant Medical Group are calculating how much they will have to spend on Sovaldi under their agreements to keep healthcare spending down.

Which patients should be screened for hepatitis C virus infection?

Insufficient current screening strategies for people with high prevalence of chronic hepatitis C virus (HCV) infection should prompt hospitalists to improve screening rates in this population. HCV is a major public health concern in the United States and worldwide. It is estimated that more than 4.1 million people in the U.S. and more than 180 million worldwide are HCV antibody-positive.

IROA and the University of Florida take on liver disease biomarkers

IROA Technologies and the University of Florida (UF) agreed to collaborate on the analysis and validation of clinical tissue for finding potential biomarkers of liver cancer and other liver diseases. The collaboration will leverage IROA's patented technology, software and expertise along with the UF's Clinical and Translational Science Institute Biorepository, which contains a diverse collection of normal and diseased human tissues and may be used for IRB-approved research.

Liver cancer, disease mortality rates climbed in US in past 30 years

Healio

Liver cancer and liver disease mortality rates have increased over the last 3 decades in the U.S., according to new findings. Yuhree Kim, M.D., MPH, department of surgery, Johns Hopkins University School of Medicine, and colleagues analyzed population-based mortality data from the National Vital Statistics System and data related to hepatitis B and C, obesity prevalence and liver cancer from the CDC between 1981 and 2010. Adults included were aged 46-years or older.

Participant's contribution to the Training

-1 (Dr Manoj Gupta) presented poster on

1. Circulating regulatory T cells as markers of immune response to tolerance in Living Donor Liver Transplant recipients

2. Predictors of intraoperative blood loss in living donor liver transplant recipients and its correlation with postoperative outcome.